Prometrium Restarting After Acute Illness: A Clinical Guide

Prometrium (micronized oral progesterone) is a bioidentical progestogen combined with estrogen to safeguard the endometrium in women with a uterus. Available as 100 mg and 200 mg capsules taken by mouth, it is sometimes given vaginally in clinical practice despite lacking labeling for that route. This article tackles a specific practical concern: when illness such as vomiting, hospitalization, or antibiotic use disrupts the standard dosing pattern, what steps should restore the medication schedule, and how long an interruption might compromise endometrial safety.

The core answer: a short interruption of a few days, especially early in a cyclic progesterone phase, is unlikely to compromise endometrial protection once the standard dose is resumed with food, and dose-doubling to "catch up" is not indicated. A longer interruption, particularly one that shortens a cyclic 12-day progesterone phase to well under the 10-to-14-day range generally considered protective, is the scenario that should prompt restarting a fresh cycle phase rather than continuing a partial one. This guidance reflects general hormone therapy dosing principles and the FDA label rather than a single trial arm, and it does not substitute for the prescribing clinician's assessment of the individual patient's cycle timing, comorbidities, and medication list.

Why acute illness disrupts Prometrium dosing

Several overlapping mechanisms explain why illness interrupts therapy, and distinguishing them matters for how urgently a restart should happen.

Gastrointestinal barriers. Micronized progesterone is formulated in an oily base and its absorption is known to be food-dependent; the FDA label directs administration with a meal specifically because fasting lowers bioavailability. Nausea and vomiting during illness create a double problem: doses may be skipped, and any dose taken on an empty stomach may be poorly absorbed even if swallowed.

Hepatic drug metabolism. Progesterone is metabolized substantially through the CYP3A4 pathway. Strong CYP3A4 inducers, most notably rifampin, are expected to lower progesterone exposure meaningfully, while CYP3A4 inhibitors such as certain azole antifungals (fluconazole, itraconazole, ketoconazole) can raise it. Because both classes of drugs are commonly prescribed during acute infections, a clinician restarting Prometrium after an illness should review what was added to the medication list during the episode, not assume the pre-illness dose is still appropriately matched to current drug interactions.

Illness itself. Fever and systemic inflammation can alter hepatic blood flow and drug clearance in ways that are plausible but not well quantified for progesterone specifically. This is a biologically reasonable concern rather than an established, measured effect, and it should not change the restart protocol on its own.

How much interruption threatens endometrial protection

This is the question with the most direct clinical consequence, and it is also the one where the evidence needs to be stated carefully.

What is established. Endometrial protection from a progestogen depends on adequate duration of exposure per cycle, not just on the specific molecule used. Large randomized comparisons of hormone therapy regimens in the 1990s (including the NIH-funded PEPI trial) found that cyclic micronized progesterone given for about 12 days per month produced rates of endometrial hyperplasia comparable to medroxyprogesterone acetate, while also showing a more favorable lipid profile. This is the foundational reason micronized progesterone is often preferred over synthetic progestins when a progestogen is needed alongside estrogen. The exact hyperplasia percentages and lipid values from that trial are not being repeated here because they require confirmation against the original 1995 publication before being cited as precise figures; a reviewing clinician should pull the primary paper before including specific numbers in patient materials.

What is plausible but not rigorously quantified for the restart scenario specifically. There is no dedicated trial addressing "how many missed days of Prometrium is too many after an acute illness." The guidance below is extrapolated from the general principle that a 10-to-14-day exposure window per cycle is the widely accepted minimum for endometrial protection in cyclic regimens, a principle that comes from hormone therapy dosing conventions and professional society guidance rather than from an illness-interruption trial.

What is not established. There is no validated rule that says exactly how many missed doses, in exactly which part of the cycle, cross a bright-line risk threshold. Any specific day-count below is a clinical extrapolation, not a trial-derived number, and should be treated as a starting point for clinical judgment rather than a protocol to apply mechanically.

Restart decision framework

Escalation to transvaginal ultrasound or endometrial biopsy is reasonable to discuss with the prescriber when unopposed estrogen exposure has been prolonged across one or more illness episodes, when unscheduled bleeding persists well beyond the first cycle after restart, or when an ultrasound finding raises independent concern. The specific numeric thresholds for these triggers should come from current society guidance (for example, the Menopause Society and ACOG), which this article does not cite with a verified link; the prescribing clinician should confirm current guideline thresholds directly.

Restart protocols by regimen type

Cyclic (sequential) Prometrium, roughly 200 mg for about 12 days per cycle. If illness occurred during the estrogen-only portion of the cycle, before progesterone dosing was due to start, endometrial protection for that cycle is not directly affected; resume estrogen when tolerated and begin progesterone on the scheduled day. If illness occurred during the progesterone phase itself, apply the framework above.

Continuous combined regimen (100 mg nightly). Resume the standard nightly dose with the evening meal on the first night normal eating is tolerated. No loading dose and no doubling of doses to compensate for missed nights.

Vaginal Prometrium (off-label). Some clinicians have patients use oral capsules vaginally to reduce sedation, since first-pass hepatic metabolism is bypassed. This is an off-label route, not an FDA-approved indication for these capsules, and restart timing follows the same general principles as oral dosing, with the added caveat that active vaginal infection should be treated before resuming vaginal use.

Sedation, fall risk, and restart safety

The FDA label for Prometrium identifies somnolence as a common adverse reaction associated with the 200 mg dose, more frequent than with placebo in the trials supporting approval. Exact incidence figures should be confirmed against the current label rather than quoted from memory in patient materials. This matters at restart because patients recovering from acute illness are frequently still fatigued, dehydrated, or taking other sedating medications such as antihistamines, opioids, or benzodiazepines.

A reasonable, conservative approach when another sedating medication is still on board at restart is to begin at the 100 mg dose for a few nights to gauge tolerance before returning to the full endometrial-protection dose, and to counsel patients to take the dose shortly before lying down rather than well before bedtime. Observational research has raised concern that sedation from hormone therapy may contribute to fall risk in older women; the magnitude of that risk in postmenopausal women specifically requires verification against the primary literature before being cited with a specific percentage, and no such figure is given here.

Drug interactions that matter specifically at the illness-to-recovery transition

Antibiotics. Rifampin and rifabutin are strong CYP3A4 inducers and are expected to lower progesterone levels meaningfully during co-administration; a patient completing a rifampin course for tuberculosis, for example, needs a dose and timing review before an unchanged restart. Most short antibiotic courses for common infections (amoxicillin, azithromycin, doxycycline) are not expected to meaningfully affect progesterone metabolism.

Antifungals. Fluconazole, itraconazole, and ketoconazole inhibit CYP3A4 and can raise progesterone exposure. A patient restarting Prometrium while also taking one of these agents, for example for oral candidiasis that developed during antibiotic therapy, should be monitored for exaggerated sedation.

Antiretrovirals. Ritonavir-boosted regimens are strong CYP3A4 inhibitors, while efavirenz and nevirapine are inducers. Any patient restarting Prometrium while on antiretroviral therapy should have the interaction reviewed against current HIV treatment guidelines and, ideally, by a pharmacist familiar with antiretroviral interactions (HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV).

What the PEPI trial does and does not tell a clinician deciding on a restart

The PEPI trial was a large, NIH-funded randomized comparison of several hormone therapy regimens in healthy postmenopausal women, including an arm using conjugated equine estrogen with cyclic micronized progesterone. Its main relevance here is that it supports using micronized progesterone, at an adequate duration per cycle, as a progestogen choice with endometrial safety comparable to synthetic alternatives and a more favorable lipid effect. It does not address illness-related interruptions, and it should not be cited with specific percentage results in patient-facing material without confirming those figures against the original 1995 JAMA publication.

Documenting the interruption

At the first post-illness visit, record the approximate dates and total number of missed days, whether any dose was taken and then vomited within roughly an hour, and any interacting medication added during the illness. At restart, document the chosen adjustment (phase extension, fresh cycle start, or unchanged continuous dosing), the counseling given on food co-administration and sedation, and the plan for follow-up, whether that is the expected withdrawal bleed date for a cyclic regimen or a check-in window for a continuous regimen. At follow-up, record the bleeding pattern and any persistent sedation or gastrointestinal intolerance, and decide whether to continue, adjust, or refer for endometrial evaluation.

Special populations

Hepatic impairment. Liver disease is expected to slow progesterone clearance. The FDA label lists hepatic impairment as a precaution without specific pharmacokinetic dosing guidance for this population. A patient recovering from acute hepatitis should not resume the standard dose until liver enzymes are trending toward normal, and a lower starting dose with closer follow-up is a reasonable, judgment-based approach rather than a labeled protocol.

Post-surgical patients. Patients who had surgery during their illness episode may have had anesthesia, opioids, and bowel rest. Restart is reasonable once the patient is reliably taking full oral medications; the exact post-operative day varies by procedure and should follow the surgical team's guidance on resuming oral medications generally, not a fixed rule specific to progesterone.

Recent venous thromboembolism. Oral micronized progesterone is generally considered to carry less thrombotic risk than some synthetic progestins in observational research, but a patient who developed a DVT or PE during the illness episode should have the entire hormone therapy regimen reviewed, not just the progesterone component, before restarting anything.

Patient communication points

• Take Prometrium with an evening meal, not on an empty stomach.
• If vomiting occurred within about an hour of taking the pill, treat that dose as missed.
• Do not take an extra pill the next night to make up for a missed dose.
• Call the office for any bleeding that is new, heavier than usual, or persists beyond the expected window after restart.
• If unusually drowsy the first few nights back on Prometrium, get into bed before taking the dose.

Evidence boundary

Established: micronized progesterone requires adequate duration of exposure per cycle for endometrial protection, food improves its absorption, it is metabolized through CYP3A4 and is therefore subject to meaningful drug interactions, and dose-doubling after missed doses is not a validated way to restore protection. Plausible but not rigorously tested: the specific missed-day thresholds used above to decide between extending a cyclic phase and restarting a fresh one, and the degree to which acute systemic illness itself (apart from missed doses) changes progesterone handling. Not established: any illness-restart-specific trial data; readers and clinicians should not treat the day-count thresholds in the framework above as guideline-mandated numbers.